A Single Dose of Methylone Reduces PTSD Symptoms Within 10 Days — No Psychotherapy Required
- Phase 2 RCT (IMPACT-1): 65 adults with severe PTSD across 16 sites in US, UK, and Ireland. TSND-201 (methylone) produced a 9.64-point greater CAPS-5 reduction vs placebo (p < 0.05)
- Statistically significant improvement detected as early as Day 10 (-8.00 points placebo-adjusted) and sustained through Day 64
- Significant secondary improvements: PCL-5, Sheehan Disability Scale, MADRS (depression comorbidity)
- Well tolerated — adverse events (headache, nausea, dizziness) transient, resolved within 24 hours. No hallucinations. No discontinuations. FDA Breakthrough Therapy Designation granted
A single dose of a neuroplastogen — no concurrent psychotherapy sessions, no multi-week protocol, no prolonged exposure — produced clinically meaningful PTSD symptom reduction in 10 days. This JAMA Psychiatry Phase 2 trial challenges the assumption that pharmacological PTSD treatment must be paired with structured therapy to work.
What the trial shows
TSND-201 is methylone, an entactogen structurally related to MDMA but with a distinct pharmacological profile. Unlike MDMA-assisted therapy, which requires multiple 8-hour sessions with trained therapists, TSND-201 was administered as a single dose in a clinical setting without concurrent psychotherapy.
The 9.64-point CAPS-5 reduction is clinically meaningful — the FDA considers a 10-point change clinically significant for PTSD trials. This was achieved in a population with severe baseline symptoms (mean CAPS-5 ~38) who had not responded adequately to prior treatments.
The speed matters. Day 10 showed significant separation from placebo. Current first-line PTSD pharmacotherapies (SSRIs) take 4-8 weeks to show effect. Trauma-focused psychotherapies require 8-16 sessions. A single-dose treatment with 10-day onset occupies an entirely different clinical niche.
What this means for practice
This is not a replacement for trauma-focused therapy. It is a potential bridge — for the patient who is too destabilised for exposure work, too avoidant for engagement, or in too much acute distress to wait 6 weeks for an SSRI to take effect.
If Phase 3 confirms these results, methylone could become the first rapid-acting pharmacological treatment specifically for PTSD. For clinicians working with complex trauma populations, watch this space — the trial's tolerability profile and single-dose model are designed for real-world clinical integration.
A single dose of methylone reduced PTSD symptoms by nearly 10 CAPS-5 points within 10 days — without concurrent psychotherapy — earning FDA Breakthrough Therapy Designation.
Small sample (n=65), predominantly White participants. Phase 2 — efficacy must be confirmed in larger Phase 3 trials. Duration of effect beyond 64 days unknown. Single-dose model may not apply to all PTSD subtypes.